» Articles » PMID: 34079754

Complement C1q (C1qA, C1qB, and C1qC) May Be a Potential Prognostic Factor and an Index of Tumor Microenvironment Remodeling in Osteosarcoma

Overview
Journal Front Oncol
Specialty Oncology
Date 2021 Jun 3
PMID 34079754
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment (TME) has important effects on the tumorigenesis and development of osteosarcoma (OS). However, the dynamic mechanism regulating TME immune and matrix components remains unclear. In this study, we collected quantitative data on the gene expression of 88 OS samples from The Cancer Genome Atlas (TCGA) database and downloaded relevant clinical cases of OS from the TARGET database. The proportions of tumor-infiltrating immune cells (TICs) and the numbers of immune and matrix components were determined by CIBERSORT and ESTIMATE calculation methods. Protein-protein interaction (PPI) network construction and Cox regression analysis were conducted to analyze differentially expressed genes (DEGs). The complement components C1qA, C1qB and C1qC were then determined to be predictive factors through univariate Cox analysis and PPI cross analysis. Further analysis found that the levels of C1qA, C1qB and C1qC expression were positively linked to OS patient survival time and negatively correlated with the clinicopathological feature percent necrosis at definitive surgery. The results of gene set enrichment analysis (GSEA) demonstrated that genes related to immune functions were significantly enriched in the high C1qA, C1qB and C1qC expression groups. Proportion analysis of TICs by CIBERSORT showed that the levels of C1qA, C1qB and C1qC expression were positively related to M1 and M2 macrophages and CD8+ cells and negatively correlated with M0 macrophages. These results further support the influence of the levels of C1qA, C1qB and C1qC expression on the immune activity of the TME. Therefore, C1qA, C1qB and C1qC may be potential indicators of remodeling in the OS TME, which is helpful to predict the prognosis of patients with OS and provide new ideas for immunotherapy for OS.

Citing Articles

New insights into the role of complement system in colorectal cancer (Review).

Xu Y, Zhou J, Wu Y, Shen J, Fu X, Liu M Mol Med Rep. 2025; 31(3.

PMID: 39791217 PMC: 11751662. DOI: 10.3892/mmr.2025.13433.


Characterization of 3,3'-iminodipropionitrile (IDPN) damaged utricle transcriptome in the adult mouse utricle.

Tian M, Huang J, Xiao H, Jiang P, Ma X, Lin Y Front Mol Neurosci. 2025; 17():1487364.

PMID: 39764513 PMC: 11701596. DOI: 10.3389/fnmol.2024.1487364.


Single-cell analysis uncovers liver susceptibility to pancreatic cancer metastasis via myeloid cell characterization.

Ainiwaer A, Qian Z, Wang J, Zhao Q, Lu Y Discov Oncol. 2024; 15(1):696.

PMID: 39578286 PMC: 11584836. DOI: 10.1007/s12672-024-01566-0.


Identification of novel biomarkers for atherosclerosis using single-cell RNA sequencing and machine learning.

Yong X, Kang T, Li M, Li S, Yan X, Li J Mamm Genome. 2024; 36(1):183-199.

PMID: 39400603 PMC: 11880100. DOI: 10.1007/s00335-024-10077-w.


Novel FABP4C1q macrophages enhance antitumor immunity and associated with response to neoadjuvant pembrolizumab and chemotherapy in NSCLC via AMPK/JAK/STAT axis.

Zhang D, Wang M, Liu G, Li X, Yu W, Hui Z Cell Death Dis. 2024; 15(10):717.

PMID: 39353883 PMC: 11445384. DOI: 10.1038/s41419-024-07074-x.


References
1.
Wang W, Ren S, Wang Z, Zhang C, Huang J . Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. Int Immunopharmacol. 2019; 78:106077. DOI: 10.1016/j.intimp.2019.106077. View

2.
Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A . Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One. 2012; 7(2):e30563. PMC: 3282707. DOI: 10.1371/journal.pone.0030563. View

3.
Hong Q, Sze C, Lin S, Lee M, He R, Schultz L . Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One. 2009; 4(6):e5755. PMC: 2685983. DOI: 10.1371/journal.pone.0005755. View

4.
Kager L, Tamamyan G, Bielack S . Novel insights and therapeutic interventions for pediatric osteosarcoma. Future Oncol. 2016; 13(4):357-368. DOI: 10.2217/fon-2016-0261. View

5.
Agostinis C, Vidergar R, Belmonte B, Mangogna A, Amadio L, Geri P . Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth. Front Immunol. 2017; 8:1559. PMC: 5701913. DOI: 10.3389/fimmu.2017.01559. View